Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Revenue projections:

Revenue projections for ZTS
Revenue projections for ZTS

Investors may be wary of ZTS as its revenues are expected to fall below the prior year's levels. A revenue decrease often leads to concerns about profitability, as it is likely to affect the company's bottom line, prompting investors to take a more cautious approach.

Financial Ratios:

currentRatio 3.028000
forwardPE 15.329163
debtToEquity 279.586000
earningsGrowth 0.061000
revenueGrowth 0.030000
grossMargins 0.718920
operatingMargins 0.346880
trailingEps 6.020000
forwardEps 7.571190

ZTS's current ratio of 3.028 highlights the company's ability to easily cover its short-term debt using its available cash and assets. This indicates a strong liquidity position, ensuring ZTS is unlikely to face difficulties in meeting immediate financial obligations.
ZTS's Forward PE is positioned well, reflecting a favorable balance between stock price and earnings. The stock isn't overpriced, offering room for growth and making it a potentially rewarding investment as its value has room to rise further.
ZTS's high debt-to-equity ratio signals that the company is heavily leveraged. This suggests ZTS may be relying more on debt than equity to finance its operations, which could expose the company to greater financial risk in challenging economic conditions.
ZTS's positive gross and operating margins highlight its profitability and operational efficiency. These strong margins demonstrate the company's ability to control costs while generating substantial revenue, contributing to a healthy financial performance.
Zoetis Inc.'s forward EPS being higher than its trailing EPS points to expected growth in profitability. This suggests that the company is projected to perform better in the current financial year, with higher earnings forecasted compared to the previous year.

Price projections:

Price projections for ZTS
Price projections for ZTS

Zoetis Inc.'s price has consistently hovered around the lower end of analysts' projections. This pattern may reflect concerns regarding the company's ability to achieve its anticipated growth.

Insider Transactions:

Insider Transactions for ZTS
Insider Transactions for ZTS


5 sales transactions of Zoetis Inc. were conducted, with market price at 157.73800048828124.There were no sell transactions throughout the period under consideration.The recent trend of increased buying at ZTS's current price levels may indicate a favorable market sentiment. This could point to a positive outlook for the stock, as investors show growing confidence through higher buy activity.

Recommendation changes over time:

Recommendations trend for ZTS
Recommendations trend for ZTS


The recent buy bias from analysts suggests Zoetis Inc. is seen as a strong investment, encouraging more investors to consider it. With this favorable sentiment, Zoetis Inc. appears to be a reliable option for parking money, offering stability and long-term growth potential in the stock market.